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Group B coxsackieviruses are etiologically linked with many human diseases including acute myocarditis and associated
chronic dilated cardiomyopathy. Well-established CVB3 cardiovirulent strains (CVB3c(s)) with known phenotypic differences have
been used to study the pathogenesis of virus-induced heart disease. The receptor-binding characteristics of cardiovirulent CVB3
are not known, but may represent one mechanism accounting for differences in disease virulence. In this study, interactions
between CVB3c(s) and the decay-accelerating factor (DAF or CD55) cell surface receptor were examined. Anti-DAF monoclonal
antibodies (MAbs) blocked virus binding and infection of susceptible HeLa cells. Virus binding was significantly reduced by
treatment of these cells with phosphatidylinositol phospholipase C enzyme, which rendered them DAF-deficient. CVB3c(s) exhibited
a differential propensity for the DAF receptor, as several cardiovirulent strains interacted more strongly than others. However, virus
binding and infection was always most effectively blocked by MAbs directed against the SCR 2 and 3 domains of DAF, suggesting
that binding occurs at a similar site(s) on the molecule for all strains. Virus binding and internalization were associated with DAF
down-regulation at the cell surface, as monitored by flow cytometry analysis. Cardiovirulent CVB3 did not interact with molecules
functionally and/or structurally related to DAF, including CD35, CD46, Factor H, or C4-binding protein. Adenovirus type 2 (Ad2) does
not use the DAF receptor. However, competitive binding assays between Ad2 and CVB1-6, CVB3c(s), anti-DAF MAbs, or
DAF-reduced cells indicated that DAF is associated with Ad2 receptors on the HeLa cell membrane. In summary, this study
indicates that DAF is an attachment receptor for cardiovirulent CVB3 and that DAF interaction may be important in the
pathogenesis of CVB-mediated heart disease. © 1998 Academic Press
INTRODUCTION
Myocarditis is defined as heart disease in which
there is inflammation of the myocardium with myocar-
dial cell necrosis (Aretz, 1987; Aretz et al., 1987). It is
the most common cause of acquired heart failure in
children and is regarded as an important predisposing
condition of dilated cardiomyopathy (DCM) in adults
(Liu et al., 1996; Martino et al., 1994, 1995b,c; Woodruff,
1980). Yet despite its importance in both the pediatric
and adult populations, there is little effective treatment
available, and mortality remains high. A recent pro-
spective clinical trial indicated that 56% of patients die
within 4.3 years of diagnosis (Mason et al., 1995).
Coxsackievirus group B (CVB) is the most commonly
identified pathogen in patients with myocarditis and
DCM, having been implicated in more than 50% of
cases with infectious etiology (Liu et al., 1996; Martino
et al., 1994, 1995b,c; Woodruff, 1980).
The initial event in these disease processes is the
binding of virus to its receptor(s) on host cells. The first
CVB receptor to be identified was the decay-accelerating
factor (DAF or CD55) (Bergelson et al., 1995; Shafren et
al., 1995). DAF is a ;70-kDa glycophosphatidylinositol-
anchored membrane protein with broad tissue distribu-
tion. It functions in the complement regulatory system, by
preventing formation or causing dissociation of C3 con-
vertases in both the classical and alternative system
pathways (Hourcade et al., 1989; Lublin and Atkinson,
1989; Nicholson-Weller and Wang, 1994).
CVB serotypes differ in their ability to bind to the
DAF receptor. Monoclonal antibodies (MAb) to DAF
blocked binding to and infection of HeLa cells in vitro
by CVB 1, 3, and 5 protoserotypes (Bergelson et al.,
1995; Shafren et al., 1995). DAF expression on trans-
fected rodent cells promoted virus binding (Bergelson
et al., 1995; Shafren et al., 1995). In contrast, protose-
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rotypes CVB 2, 4, and 6 did not bind to DAF (Bergelson
et al., 1995; Shafren et al., 1995).
Virus strains which occur within each CVB serotype
differ in their ability to bind to the DAF receptor. One
prototype CVB3-VR30 strain was found to bind to trans-
fected cells expressing the DAF molecule (Shafren et
al., 1995), whereas a second CVB3-VR30 strain did not
bind to DAF on transfected cells (Bergelson et al.,
1995). Serial passage of the non-DAF-binding CVB3-
VR30 strain through human rhabdomyosarcoma cells
selected a strain (CVB3-RD; Reagan et al., 1984) that
was capable of binding to DAF on transfected cells
(Bergelson et al., 1995). Moreover, CVB strains iso-
lated from infants with aseptic meningitis have been
shown to differ in their ability to bind to DAF (Bergel-
son et al., 1997b). Some clinical isolates of CVB 1, 3,
and 5 were inhibited from infecting HeLa cell mono-
layers by an anti-DAF MAb (MAb IF7), whereas several
other strains did not appear to interact with DAF (Ber-
gelson et al., 1997b).
CVB3 cardiovirulent strains (CVB3c(s)) are used in a
number of laboratories to study viral heart disease.
These strains differ in cardiopathogenicity in several
murine model systems (Chow et al., 1991). The char-
acteristics of the CVB3 strains used in this study are
listed in Table 1. The capacity of each of these strains
for binding receptors and infecting cells is expected to
be an important part of the disease process. However,
it is not known if receptor molecules such as DAF play
a role in the binding and infection of host cells by
cardiovirulent CVB3. In this study, we examined the
interactions of CVB3c(s) with the DAF receptor mole-
cule. It has previously been reported that prototype
CVB3 and Ad2 fiber compete for receptor binding
(Lonberg-Holm et al., 1976). In this study, we also
examined the ability of CVB3c(s) to compete with Ad2
binding and the ability of Ad2 to bind to DAF.
RESULTS
MAb inhibition of [35S]CVB3c(s) binding to HeLa cells
We first examined whether anti-DAF MAb inhibits car-
diovirulent CVB3 virus binding to susceptible cells (Fig.
1). Pretreatment with MAb 914 to DAF blocked the bind-
ing of all cardiovirulent [35S]CVB3 strains to HeLa cells.
However, the degree of binding inhibition differed for
each strain. Preincubation with MAb 914 strongly re-
duced the binding of radiolabeled CVB3-CG, CVB3-
CGP1V, CVB3-SH, CVB3-A, and CVB3-VR30 to the cell
surface, moderately reduced binding of CVB3-N and
CVB3-NR, and only weakly reduced binding of CVB3-20
to HeLa cells. In contrast, there was no reduction of
[35S]CVB3-CG binding when cells were pretreated with
control MAb 653 (anti-CD4) (inhibition, 0%; results not
shown).
TABLE 1
Characteristics of CVB3c(s) Strains





Adapted by Woodruf and passaged in two laboratories giving rise to
-CG and -SH strains.
Cause severe histologic damage to heart in adolescent mouse
models.
Chow et al. (1991);
Gauntt et al. (1984);
Van Houten et al.
(1991)
Very strong
CVB3-NR Animal passage selection for low mortality, but high capacity for
inducing myocarditis in susceptible neonatal or weanling mice.
Less cardiovirulent in young adult mice than CVB3-CG or -SH.
Chow et al. (1991);
Wilson et al. (1969)
Weaker
CVB3-20 Natural isolate from a patient in California in the 1950s.
Less cardiovirulent in young adult mice than CVB3-CG or -SH.
Chow et al. (1991);
Tracy et al. (1992)
Weaker
CVB3-A Infectious laboratory variant related to CVB3-20.
Originally regarded as noncardiovirulent, but a single base pair
transition at nucleotide 234 (C-U in the 59 nontranslated region)
repairs a ribosomal binding site and restores the cardiovirulent
phenotype.
Chapman et al. (1994);
Tu et al. (1995)
Very strong
CVB3-N Cardiovirulent large plaque strain derived from CVB3-VR30.
Cloned, sequenced, and studied in murine models of virus persistence
and chronic heart disease.
Kandolf et al. (1985,
1993); Klingel et al.
(1992); Klump et al.
(1990)
Weaker
CVB3-CGP1V Generated by passaging CVB3-CG once through Vero cells to examine
phenotypic / genotypic changes from virus passage through cell
lines.
Very strong
CVB3-VR30 Obtained directly from ATCC and passaged once through HeLa cells
to acquire stock virus.
Isolated from the stool of a febrile patient with minor illness, in
Connecticut in 1949. Presumably noncardiovirulent.
Additional receptor(s)
needed for efficient
binding to the cell
surface
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MAb inhibition of CVB3c(s) infection of HeLa cells
We then examined whether anti-DAF MAbs inhibit car-
diovirulent CVB3 virus from infecting susceptible cells
(Fig. 2). Anti-DAF MAb 914 strongly inhibited plaque for-
mation by the CVB3-CG, CVB3-CGP1V, CVB3-SH,
CVB3-A, and CVB3-VR30 strains and moderately inhib-
ited plaque formation in HeLa cells by the CVB3-N,
CVB3-NR, and CVB3-20 strains. In contrast, anti-DAF
MAb IA10 was generally less effective at inhibiting
CVB3c(s) plaque formation in HeLa cells, when used at
the same concentration as MAb 914. Control MAb 653
(anti-CD4) did not affect CVB3c(s) plaque formation in
HeLa cells (percentage of inhibition of plaques, 0%; re-
sults not shown).
[35S]CVB3c(s) binding to PI-PLC-treated HeLa cells
Since MAbs against DAF could theoretically cause
steric hindrance of the binding of virus to other cell
surface molecules, we also examined CVB3c(s) bind-
ing to DAF-depleted HeLa cells. To do this, cell were
pretreated with phosphatidylinositol phospholipase C
(PI-PLC), an enzyme which cleaves GPI-anchored mol-
ecules such as DAF from the cell surface (Davitz et al.,
1986; Medof et al., 1986). DAF depletion of HeLa cells
by Pl-PLC enzyme was confirmed by flow cytometry
analysis (Fig. 3). Following Pl-PLC treatment, the in-
tensity of DAF staining decreased (left shift in the
peak) by approximately 75%. A reduction in binding of
the 35S-labeled CVB3-CG, CVB3-SH, CVB3-A, and
CVB3-CGP1V strains to the Pl-PLC-treated HeLa cells
was also observed (Fig. 4). In contrast, Pl-PLC treat-
ment of HeLa cells reduced binding of 35S-labeled
CVB3-NR and CVB3-N strains by only 30% and the
binding of [35S]CVB3-VR30 and CVB3-20 strains by
less than 20% (Fig. 4).
Effect of virus infection on DAF expression on HeLa
cells
The effect of CVB3c(s) on DAF expression at the cell
surface was also monitored. Infection of HeLa cells by all
CVB3c(s) for 3 h led to a reduced expression of DAF on
the cell surface, by 10–25%, compared to uninfected
control cells (Fig. 5). Binding of virus most likely internal-
izes the DAF receptor, since eclipse of bound CVB3 in
HeLa cells generally requires only several minutes at
37°C (Zajac and Crowell, 1969).
FIG. 1. Inhibition of [35S]CVB3c(s) binding to HeLa cells by anti-DAF MAb 914. Versene-dispersed HeLa cells washed and aliquoted at 5 3 10
6
cells/test were resuspended in 200 ml media containing 50 mg/ml of anti-DAF MAb 914, or 200 ml media only, at 37°C for 1 h. After washing, 103–104
cpm of [35S]CVB3c(s) was added to the cells for 1 h at 37°C. Cells were centrifuged at 1000 g for 3 min and the supernatant fluid and two subsequent
washes were collected, as was the cell pellet. Unbound virus and cell bound virus were determined by monitoring the 35S cpm in supernatants and
cell pellets, by scintillation spectroscopy. Experiments were performed in triplicate for each virus strain. Inhibition of [35S]CVB3c(s) binding to cells was
calculated as
100% 2 F fraction of added @35S#2CVB3c~s! that binds to treated cellsfraction of added @35S#2CVB3c~s! binding to untreated ~control! cells 3 100G .
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Complement studies
We examined the ability of CVB to interact with the
DAF-related complement molecules CD46, CD35, Factor
H, and C4bp. The cardiovirulent CVB3-CG strain did not
interact directly with any of these molecules (percentage
of inhibition, 0; results not shown). There was no reduc-
tion in virus infection on HeLa monolayers pretreated
with anti-CD46 MAb. Moreover, there was no detectable
binding of [35S]CVB3-CG to human blood cells. Finally,
when virus was pretreated with Factor H or C4bp, there
was no reduction in infection in HeLa cell plaque assays
compared to untreated virus controls.
Ad2-CVB competition binding assays
To examine the competitive binding interactions be-
tween Ad2 and CVB, competition assays were per-
formed. Pretreatment of HeLa cells with unlabeled Ad2
virus strongly inhibited radiolabeled [35S]Ad2 binding to
the cells (Fig. 6). [35S]Ad2 binding to cells was also
inhibited in cells pretreated with CVB serotypes 1–6 (Fig.
6). Virus binding to HeLa cells was most strongly inhib-
ited by pretreatment with odd serotypes CVB 1, 3 and 5,
whereas even-CVB serotypes 2, 4, and 6 were less com-
petitive. [35S]Ad2 binding to HeLa cells was also reduced
in cells pretreated with CVB3c(s) (Fig. 7). Virus binding
was strongly inhibited by strains CVB3-CG, CVB3-A, and
CVB3-VR30 and moderately inhibited by pretreatment
with CVB3-CGP1V and CVB3-SH, but was not inhibited
by strains CVB3-N, CVB3-NR, and CVB3-20.
Ad2 binding to DAF
We also monitored the ability of Ad2 to bind to DAF by
examining Ad2 binding to HeLa cells pretreated with
anti-DAF MAbs or Ad2 binding to DAF-reduced (PI-PLC-
pretreated) HeLa cells. [35S]Ad2 binding to HeLa cells
was moderately inhibited by pretreatment of HeLa cells
with anti-DAF MAb IA10 (Fig. 8). In contrast, virus binding
was not inhibited by anti-DAF MAb 914 (Fig. 8). [35S]Ad2
binding to HeLa cells rendered DAF-deficient by treat-
ment with the enzyme Pl-PLC was significantly in-
creased, compared to virus binding to untreated HeLa
cells (Fig. 8).
DISCUSSION
CVB3 is implicated in the pathogenesis of myocarditis
and dilated cardiomyopathy (Liu et al., 1996; Martino et
al., 1994, 1995b,c; Woodruff, 1980). Many CVB3 strains
can infect and replicate in the heart, as demonstrated in
FIG. 2. Inhibition of CVB3c(s) plaque formation on HeLa cells pretreated with anti-DAF MAbs 914 or IA10. HeLa cell monolayers plated in 6-well
Costar dishes at a density of 1 3 106 cells/well were preincubated with 1 ml media containing 50 mg/ml of MAb IA10 or 914, or 1 ml of media only,
at 37°C for 1 h. After washing, 1 ml containing 50 PFU/ml of each virus was added at 37°C for 1 h. The monolayers were washed, plaque overlays
were added for 3 days, and then plaques were enumerated. The CVB3-20 strain plaques inefficiently on HeLa cells, so infectivity for this strain was
monitored by a TCID50 assay. All experiments were performed in triplicate. Inhibition of CVB3c(s) infection of HeLa cells was determined as
100% 2 FNo. CVB3c~s! PFU on MAb2treated cellsNo. CVB3c~s! PFU on untreated cells 3 100G .
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murine model systems. However, only some strains are
found to be cardiovirulent, because only these strains
initiate disease processes which lead to inflammation of
the myocardium and severe destruction of myocardial
tissue. The genesis of viral heart disease likely repre-
sents a complex interplay of both virus-encoded and
host-derived factors. In this study we examined one of
these factors: the capacity of cardiovirulent CVB3 strains
to interact with the DAF cell surface receptor.
The characteristics of the CVB3 strains used in this
study are summarized in Table 1. Three lines of evidence
show that the cardiovirulent CVB3 strains used in this
FIG. 3. Characterization of DAF-depleted HeLa cells by flow cytometry analysis. Versene-dispersed HeLa cells aliquoted at 5 3 106 cells/test were
treated with 0.2 ml RPMI containing 0.5 units of phosphatidylinositol phospholipase C (Pl-PLC, from Bacillus cereus; Boehringer Mannheim, Laval
Quebec, Canada) at 37°C for 1 h. Cells were washed three times and labeled with 10 ml of undiluted FITC-conjugated anti-DAF MAb 737F on ice for
30 min. The cells were washed and resuspended in 1 ml PBS, and DAF expression/loss was monitored by flow cytometry. (A) Untreated HeLa cells.
(B) HeLa cells treated with Pl-PLC. (C) HeLa cells labeled with control MAb (FITC-conjugated rabbit (Fab’)2 anti-rat IgG; Serotec).
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study interacted with DAF on the cell surface. (1) Binding
of radiolabeled [35S]CVB3c(s) to HeLa cells decreased
when cells were preincubated with anti-DAF MAbs, com-
pared to control MAbs or media. (2) Plaque formation by
CVB3c(s) was reduced when HeLa cell monolayers were
preincubated with anti-DAF MAbs, showing that block-
age of DAF reduced CVB3c(s) infection. (3) Binding of
CVB3c(s) to DAF-depleted Pl-PLC-treated HeLa cells was
reduced, compared to untreated HeLa cell controls.
The present study showed that although all the strains
tested showed interactions with DAF, some CVB3c(s)
interacted more strongly with DAF than others. DAF in-
teractions were most pronounced for the viruses which
produce severe disease in the murine model (CVB3-CG,
CVB3-SH), compared to those which produce less se-
vere disease (CVB3-20, CVB3-NR) in vivo.
Interestingly, the CVB3-A strain interacted significantly
more strongly with DAF than the parental CVB3-20 strain.
There are several mutations in the capsid region of
CVB3-A relative to CVB3-20 (Chapman et al., 1994; Tracy
et al., 1992; Tu et al., 1995), and it is possible that one or
more of these mutations could result in a significantly
stronger DAF-binding phenotype.
The CVB3-N strain exhibited a weaker DAF-binding
phenotype, similar to the interactions observed for CVB3-
NR. Interestingly, nucleotide sequencing and phyloge-
netic analysis of the (receptor-binding) capsid region of
the strains indicated that CVB3-NR and CVB3-N are most
closely related to each other, as compared to the other
CVB3c(s) (Martino et al., 1997), consistent with the similar
binding patterns observed for these two viruses.
The CVB3-VR30 strain is presumably noncardioviru-
lent, and its interactions with DAF were distinct from
those noted for the cardiovirulent strains of virus. Anti-
DAF MAbs strongly blocked virus binding (Fig. 1) and
infection (Fig. 2) of HeLa cells. However, CVB3-VR30
binding was only weakly affected by Pl-PLC digestion of
cells (Fig. 4). Although the reason for this discrepancy is
unclear, it may indicate that of all the strains tested, the
CVB3-VR30 strain most requires an additional receptor(s)
other than DAF for efficient binding to the cell surface.
This is consistent with previous reports that MAbs can
block CVB3-VR30 binding to the cell surface, but that this
strain binds to DAF only weakly (Shafren et al., 1995) or
not at all (Bergelson et al., 1995).
The extent to which anti-DAF MAbs interfered with
binding/infection of HeLa cells by a CVB3c(s) depended
on the epitope to which the antibody was directed. MAb
914 (clone BRIC 216) binds to the DAF molecule at SCR3
(Coyne et al., 1992) and was most effective at reducing
CVB3c(s) infection of HeLa cells. In preliminary studies,
MAb 737 (clone BRIC 110), which binds to SCR2 (Coyne
et al., 1992), produced similar results when tested with
the CVB3-CG strain (unpublished observations). In con-
trast, MAb IA10, which binds DAF at SCR1 (Coyne et al.,
1992), does not block CVB3 efficiently. These findings are
consistent with previous reports that anti-DAF MAbs
recognizing SCR2 and SCR3 are most effective at block-
ing virus attachment and internalization and that a CVB-
binding site is likely located within or near these do-
mains (Bergelson et al., 1995; Shafren et al., 1995).
Complement regulatory molecules which are structur-
FIG. 4. Reduction in [35S]CVB3c(s) binding to Pl-PLC-treated DAF-depleted cells. Pl-PLC-treated HeLa cells (unlabeled) were prepared as described
in Fig. 3. They were used in binding assays as described in Fig. 1. The experiments were performed in quadruplicate for each virus strain.
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ally and/or functionally related to DAF, including CR1
(CD35), MCP (CD46), C4-binding protein, and Factor H
(Hourcade et al., 1989), do not interact with the cardio-
virulent CVB3-CG strain, indicating that the site of virus
binding is unique to the DAF molecule. The possibility
exists that other strains not tested could interact with
DAF-related ligands.
Cardiovirulent CVB3 strains bind to DAF. In light of this
observation, two important questions arise. First, DAF is
not a receptor in the classical sense, because it alone
does not promote lytic infection of cells (Bergelson et al.,
1995; Shafren et al., 1995). How then, does CVB3c(s)
binding to DAF play a role in the pathogenesis of CVB-
induced heart disease? Second, are all DAF-binding
viruses cardiovirulent?
In addressing the first question, there are several
possible mechanisms by which DAF binding could play
a role in the pathogenesis of viral heart disease. (1) DAF
binding may facilitate or promote virus presentation to
an additional cell surface receptor(s), thus enhancing
virus virulence. (2) DAF distribution may promote viral
tropism for specific organ sites. (3) Binding of CVB3c(s) to
DAF could play a role in the initiation of signaling cas-
cades, with pathogenic consequences. For example,
DAF is a glycolipid-anchored protein which associates
with the T-cell-activating tyrosine kinases p56lck and
p59fyn (Davis et al., 1988; Shenoy-Scaria et al., 1992).
T-cell activation, which is a hallmark feature of myocar-
ditis, does not occur in transgenic mice lacking the
signaling molecule p56lck. These mice are resistant to
CVB heart disease (Martino et al., 1995a). (4) Loss of DAF
expression on CVB-infected cells, as was noted in this
study, may make the cells more susceptible to comple-
ment-mediated lysis. This could facilitate release of
progeny virus from some cell types, further enhancing
virus virulence. (5) Finally, it is interesting to note that
murine DAF (Spicer et al., 1995) can be induced and
regulated by estrogen (Song et al., 1996). It has previ-
ously been reported that estrogen is protective in murine
models of CVB-induced heart disease (Huber et al.,
1982). Moreover, in both mice and humans, virus-induced
heart disease is more severe and more prevalent in
males than in females (Martino et al., 1995b).
In response to the second question, this study focused
on CVB3 variants which are known to cause heart dis-
ease in well-defined model systems. All the cardioviru-
lent strains of CVB3 tested here bound to DAF. However,
this does not presume that all DAF-binding viruses are
cardiovirulent. Indeed, prototype strains of CVB1, CVB5,
CVA21, and several echoviruses bind to DAF (Bergelson
et al., 1994, 1995; Shafren et al., 1995, 1997b). But addi-
tional characteristics of each virus strain, including bind-
ing to other receptors, internalization, replication, and
progeny production, come into play in determining dis-
FIG. 5. DAF reduction on the surface of CVB3c(s)-infected cells. Versene-dispersed HeLa cells aliquoted at 1 3 10
6/test were resuspended in 200
ml RPMI containing 1 3 108 PFU of virus, for 1 h at 25°C. Cells were washed and further incubated in complete media for 2 h at 37°C. Cells were
labeled with FITC-conjugated anti-DAF MAb 737F as described in Fig. 3, and DAF expression/loss was monitored by flow cytometry. MnX refers to
the mean fluorescence intensity of the sample under analysis. The assay was performed in triplicate, and each symbol represents one value obtained.
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ease outcome. Nevertheless, future studies examining
the cardiopathogenicity of other enteroviruses would be
interesting, particularly in light of the observation that
strains including CVB1, CVB5, CVA, and echoviruses
have been associated with heart disease in humans
(WHO/ISFC Task force, 1980).
In this study, we also examined the ability of Ad2 to
bind to DAF, as well as the competitive binding char-
acteristics between Ad2 and CVB serotypes 1–6 and
CVB3c(s). These studies stem from the original reports
that CVB and Ad2 fiber can compete for a receptor
(Lonberg-Holm et al., 1976). We found that the odd-
numbered CVB 1, 3, and 5 serotypes competed most
strongly with Ad2 for binding to the HeLa cell surface,
compared to the even-numbered CVB 2, 4, and 6
serotypes (Fig. 6). One possible explanation for this
observation is that the odd-numbered CVB serotypes
exhibit greater binding affinities than the even-num-
bered ones (Crowell, 1976) and thus more rapidly
saturate available cell surface receptors. Additionally,
it has been noted that CVB 1, 3, and 5 can bind to DAF,
whereas CVB 2, 4, and 6 do not bind DAF (Bergelson
et al., 1995; Shafren et al., 1995), and the ability to
saturate the DAF receptor could be important in com-
peting with Ad2 for cell surface binding. In support of
this latter hypothesis, we have also observed that
cardiovirulent CVB3c(s) strains which interacted most
strongly with DAF were more effective at inhibiting Ad2
binding to HeLa cells than cardiovirulent strains which
showed weaker interactions with DAF (Fig. 7).
It seems unlikely that Ad2 binds directly to DAF. Anti-
DAF MAb 914, which binds to the third domain (SCR3)
near the site of CVB attachment, does not affect Ad2
binding to the cell surface. Anti-DAF MAb IA10, which
binds to the outermost domain (SCR1), does block ap-
proximately 50% of Ad2 binding, but this is likely due to
steric hindrance. The observation that DAF-reduced
HeLa cells are significantly more capable of binding Ad2
than normal HeLa cells also points to the notion that
pretreatment with DAF-binding viruses or antibodies
sterically blocks the ability of Ad2 to bind to its natural
receptors. It also indicates that DAF- and Ad2-binding
receptors (such as coxsackie adenovirus receptor (CAR)
(Bergelson et al., 1997a; Carson et al., 1997; Tomko et al.,
1997) or the Ad2-binding integrins avb3 or avb5 (Wickham
et al., 1993), or Ad2 fiber-binding human fibronectin type
FIG. 6. Adenovirus 2 and CVB serotypes 1–6 competitive binding assays. Versene-dispersed HeLa cells aliquoted at 5 3 106 cells/test were
preincubated in 0.2 ml of media containing 1 3 108 PFU of unlabeled virus strain (Ad2 or CVB1-6) or 0.2 ml of media, for 1 h at 37°C. Cells
were washed and further incubated with 5 3 104 cpm of [35S]Ad-2 virus, for 1.5 h at 37°C. [35S]Ad2 binding was monitored by scintillation
spectroscopy, as described in Fig. 1. The experiments were performed at least three times for each virus serotype. The asterisk denotes
statistical significance (P , 0.001).
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III (Hong and Boulanger, 1995), or the MHC class I a2
domain (Hong et al., 1997)) probably colocalize on the
HeLa cell membrane. Indeed, it has previously been
reported that DAF also colocalizes with ICAM-1 (Shafren
et al., 1997b), the receptor shared by coxsackievirus A21
(Shafren et al., 1997a) and the major group rhinoviruses
(Greve et al., 1989; Stauton et al., 1989; Tomassini et al.,
1989).
In this study, cardiovirulent strains of CVB3 inter-
acted with the DAF receptor, but Ad2 virus did not,
shedding some light on the different tissue tropisms,
disease manifestations, and host ranges noted for
each virus. It is likely that CVB binding to DAF is only
one of many virus-determined factors involved in viral
heart disease. Additional mechanisms by which CVB
targets heart tissue and initiates aberrant immune
responses will undoubtedly become clearer once re-
agents to recently identified CVB receptor molecules
like CAR (Bergelson et al., 1997a; Carson et al., 1997;
Tomko et al., 1997) and a 100-kDa nucleolin-like pro-
tein (Raab de Verdugo et al., 1995) become available.
Understanding these interactions is important for an
understanding of the disease processes that occur
and perhaps will open new avenues for the treatment
of CVB heart disease.
MATERIALS AND METHODS
Cell lines
HeLa (ATCC CCL-2) and Vero (ATCC CCL-81) cells
were grown in RPMI 1640 media supplemented with
NaHCO3 to pH 7.5, 0.5% penicillin and streptomycin, and
10% fetal calf serum (FCS). All media and supplements
were from Gibco/BRL Life Technologies Canada, Burl-
ington, Ontario, Canada.
Viruses
The CVB3 cardiovirulent strains (CVB3c(s)) -SH, -NR,
-N, -CG, -20, and -A were from the laboratories of
Charles Gauntt and Larry Chow. The CVB3-VR30 strain
was obtained from the American Type Culture Collection.
The passage strain CGP1V refers to the CVB3-CG strain
passaged once through Vero cells. The characteristics of
these strains are summarized in Table 1. Adenovirus type
2 was obtained from the American Type Culture Collec-
tion. Stocks of these viruses were prepared by passag-
ing them through HeLa cell cultures (with Vero cells used
for CGP1V). Stocks were freeze–thawed 33, clarified by
centrifugation, titered by plaque assay on HeLa cells,
aliquoted, and stored at 270°C.
FIG. 7. Adenovirus 2 and CVB3c(s) competitive binding assays. Assays were performed as described in Fig. 6, but used CVB3c(s) instead of CVB1–6.
The experiments were performed in triplicate for each virus strain. The asterisk denotes statistical significance (P , 0.001).
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Virus radiolabeling and purification
HeLa cell monolayers in 10-cm2 culture dishes were
incubated with the infecting CVB virus (10 PFU/cell) for
30 min at 37°C. Monolayers were washed and then
incubated at 37°C in media deficient in methionine for
2.75 h. To each dish, 6 ml of media containing 100 mCi
of [35S]methionine (Amersham Life Science, Oakville,
Ontario, Canada) was added for an additional 3.75 h.
The infected cell monolayers were washed, collected
by scraping into 2 ml of collection buffer (1.5% sucrose,
0.01 M NaCl, 0.01 M Tris–HCl, 0.05 M MgCl2), and
subjected to three freeze–thaw cycles to release the
virus. The lysate was centrifuged at 12,000 g for 15 min
to remove the cell debris. The supernatant was over-
laid on sucrose gradients [15–45% (wt/wt) in collection
buffer] and centrifuged at 24,000 rpm at 25°C for 3 h in
an SW28 rotor (Beckman, Mississauga, Ontario, Can-
ada). Fractions with peak radioactivity and viral titer
were pooled and dialyzed in 10K Slide-A-Lyzer Cas-
settes (Pierce, Rockford, IL) against RPMI medium.
Virus titer was determined by plaque assay and ali-
quots were stored at 270°C.
For adenovirus type 2, HeLa cell monolayers were
incubated at an m.o.i. of 5 PFU/cell for 1 h at 37°C,
washed, and then incubated in regular media. After 16 h,
the medium was changed to 6 ml of methionine-deficient
RPMI which contained 100 mCi of [35S]methionine, and
cell monolayers were further incubated for 6 h. Finally,
the medium was changed to 10 ml containing (1:1) reg-
ular RPMI:methionine-deficient RPMI supplemented with
300 mCi of [35S]methionine, and cells were incubated for
48 h. The cells were collected by scraping into 2 ml of
collection buffer, then subjected to five freeze–thaw cy-
cles to release virus, and the lysate was centrifuged at
12,000 g for 15 min to remove cell debris. The superna-
tant was overlaid on sucrose gradients [15–60% (wt/wt)
in collection buffer] and centrifuged as described above.
Virus containing fractions were pooled, dialyzed, titred,
and stored as described above.
Plaque assays
HeLa cells plated in 6-well Costar dishes at a density
of 1 3 106 cells/well were incubated with serial 10-fold
dilutions of CVB3c(s) in 0.2 ml of RPMI medium (without
FCS), for 1 h at 37°C. Unbound virus in the inoculum was
removed and an overlay of 23 RPMI medium supple-
mented with 20% FCS and 1.4% agarose [1:1 (vol/vol)]
was added. The monolayers were incubated for 3 days,
fixed in 2% Formalin, and stained with 0.1% crystal violet
dye. Adenovirus type 2 was titered in the same manner,
except that the monolayers were incubated for 10 days to
allow for plaque formation.
TCID50 assays
HeLa cells plated in 96-well Costar dishes at a density
of 6.25 3 104 cells/well were incubated with serial two-
FIG. 8. Inhibition of [35S]Ad2 binding to HeLa cells. HeLa cells pretreated with anti-DAF MAbs 914 and IA10 were prepared as described in Fig.
1. Pl-PLC-treated cells were prepared as described in Figs. 3 and 4. Pretreated cells were then incubated in 200 ml RPMI containing 5 3 104 cpm
of [35S]Ad2, for 1.5 h at 37°C. Virus binding was determined as described above. The experiments were performed at least three times for each assay.
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fold dilutions of CVB3c(s) in 0.02 ml of RPMI medium
(without FCS), for 1 h at 37°C. Unbound virus in the
inoculum was removed, and RPMI medium supple-
mented with 10% FCS was added. The monolayers were
incubated for 3 days, fixed in 2% Formalin, and stained
with 0.1% crystal violet dye. The end point was taken as
the last dilution in which 50% CPE was noted.
MAbs and complement proteins
Anti-DAF MAb 1A10 was obtained from Cedarlane
Laboratories Ltd., Hornby, Ontario, Canada. Anti-DAF
MAb 914 (clone BRIC 216) and anti-DAF MAbs 737 and
737F (FITC conjugated) (clone BRIC 110) and MAb 695 to
membrane cofactor protein (anti-MCP/CD46; clone J4-
48), MAb 554 (anti-CR1/CD35; clone E11), and MAb 653
(anti-CD4; clone B-B14) were obtained from Serotec Can-
ada, Toronto, Ontario, Canada. Complement Factor H
and C4-binding protein were purchased from Sigma Im-
munochemicals.
Anti-DAF MAb inhibition of [35S]CVB3c(s) binding to
HeLa cells
Versene-dispersed HeLa cells were preincubated with
anti-DAF MAb 914 (anti-CD4 MAb 653 was used as
control). Radiolabeled [35S]CVB3c(s) was then added to
the MAb-treated cells. Supernatant fluid and two subse-
quent washes were collected, as was the cell pellet.
Unbound and cell bound virus were determined by mon-
itoring the 35S cpm in supernatants and cell pellets,
respectively, by scintillation spectroscopy.
Anti-DAF MAb inhibition of CVB3c(s) infection of HeLa
cells
HeLa cells plated on Costar dishes were preincubated
with anti-DAF MAb 914 or MAb IA10 (or anti-CD4 MAb 653
as control) and then with 50 PFU/ml of each virus. Infection
was monitored by plaque assay for all strains except CVB3-
20, which was monitored by a TCID50 assay.
Effects of DAF depletion on binding of CVB3c(s)
Versene-dispersed HeLa cells were pretreated with
Pl-PLC (from Bacillus cereus; Boehringer Mannheim, La-
val Quebec, Canada). Cells were then labeled with FITC-
conjugated anti-DAF MAb 737F as described above. DAF
expression/loss was monitored by flow cytometry. DAF-
deficient HeLa cells were then used in binding assays
with [35S]CVB3c(s) by methods described above.
CVB3c(s) binding and DAF expression
Versene-dispersed HeLa cells were preincubated with
each CVB3 strain. The cells were washed and then
further incubated in RPMI medium. Cells were labeled
with FITC-conjugated anti-DAF MAb 737F and processed
through flow cytometry, as described above.
Complement studies
Versene-dispersed HeLa cells were preincubated with
anti CD46-MAb 695, by the same methods described for
anti-DAF MAbs. After washing, radiolabeled [35S]CVB3-CG
was added to the MAb-treated cells. Virus binding was
monitored by scintillation spectroscopy, as described
above. CD35-binding assays were performed using human
blood cells, since the CD35 molecule is not expressed on
HeLa cells (unpublished observations). Whole human
blood (1 ml) was collected on ice, spun down at 1000 g for
5 min to remove plasma, washed in RPMI, and then ali-
quoted at 5 3 106 cells/test. Binding assays with [35S]CVB3-
CG were performed as described above. Factor H or C4bp
was preincubated with 50 PFU/ml of CVB3-CG for 1 h at
37°C and then virus infection was monitored by plaque
assay as described above.
Ad2-CVB competition binding assays
Versene-dispersed HeLa cells were preincubated
with unlabeled CVB virus or unlabeled Ad2 for 1 h at
37°C. The cells were washed and further incubated
with radiolabeled [35S]Ad2 for 1.5 h at 37°C. [35S]Ad2
binding was monitored by scintillation spectroscopy,
as described above.
Ad2 binding to DAF
Versene-dispersed HeLa cells were preincubated with
anti-DAF MAb 914 or anti-DAF MAb IA10 or Pl-PLC en-
zyme, as described above. The cells were washed, and
radiolabeled [35S]Ad2 was then added. [35S]Ad2 binding
was monitored by scintillation spectroscopy, as de-
scribed above.
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